Dynavax Technologies Corporation - Sales Analysis Snapshot

Business Description
This Report provides a comprehensive Sales & Margin summary analysis for Dynavax Technologies Corporation Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.

Dynavax Technologies Corporation. The Company's principal activity is to discover, develop and commercialize TLR-9 agonist-based products to treat and prevent allergies, infectious diseases and chronic inflammatory diseases. The clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. The products in pipeline includes: TOLAMBA, a ragweed allergy immunotherapeutic, currently in major large-scale clinical trial in ragweed allergic adults and in a supportive trial in ragweed allergic children; HEPLISAV, a hepatitis B vaccine, currently in a Phase 3 clinical trial; SUPERVAX, a hepatitis B vaccine; a cancer therapy currently in a Phase 2 clinical trial in non-Hodgkins lymphoma; an asthma immunotherapeutic that has shown preliminary safety and pharmacology in a Phase 2a clinical trial and preclinical programs in hepatitis B and C therapy.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report